Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Chondrosarcoma × TQ-B3525 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Ewing 1 Osteosarcoma 1 HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1 Chondrosarcoma 1

Interventions

Doxorubicin 2 temsirolimus 1 resiquimod 1 poly ICLC 1 liposomal doxorubicin 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 envafolimab 1 enasidenib 1 TQ-B3525 1 Sunitinib 1 Nivolumab 1 Methotrexate 1 Ifosfamide 1 HhAntag691 1 Epirubicin 1 Dacarbazine 1 Cisplatin 1 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04690725 2020-12-31

TQBSP

Peking University People's Hospital

Phase 1/2 Unknown

Chondrosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡